FR2988393B1 - INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT - Google Patents

INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT

Info

Publication number: FR2988393B1
Authority: FR; France
Prior art keywords: egf; egfr; enhancement; inhibitor; domain
Prior art date: 2012-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

FR1252497A

Other languages

French (fr)

Other versions

FR2988393A1 (en

Inventor

Daniel Gillet

Benoit Villiers

Sylvain Pichard

Bernard Maillere

Alain Sanson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Commissariat a lEnergie Atomique et aux Energies Alternatives CEA

Original Assignee

Commissariat a lEnergie Atomique CEA

Commissariat a lEnergie Atomique et aux Energies Alternatives CEA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-20

Filing date

2012-03-20

Publication date

2014-05-09

2012-03-20 Priority to FR1252497A priority Critical patent/FR2988393B1/en

2012-03-20 Application filed by Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA

2013-03-19 Priority to PCT/IB2013/052173 priority patent/WO2013140335A1/en

2013-03-19 Priority to JP2015501031A priority patent/JP6279543B2/en

2013-03-19 Priority to US14/386,470 priority patent/US9758552B2/en

2013-03-19 Priority to EP13720081.2A priority patent/EP2828285B1/en

2013-03-19 Priority to DK13720081.2T priority patent/DK2828285T3/en

2013-03-19 Priority to ES13720081.2T priority patent/ES2679168T3/en

2013-03-19 Priority to TR2018/10352T priority patent/TR201810352T4/en

2013-09-27 Publication of FR2988393A1 publication Critical patent/FR2988393A1/en

2014-05-09 Application granted granted Critical

2014-05-09 Publication of FR2988393B1 publication Critical patent/FR2988393B1/en

Status Expired - Fee Related legal-status Critical Current

2032-03-20 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)

FR1252497A 2012-03-20 2012-03-20 INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT Expired - Fee Related FR2988393B1 (en)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
FR1252497A FR2988393B1 (en)	2012-03-20	2012-03-20	INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT
JP2015501031A JP6279543B2 (en)	2012-03-20	2013-03-19	HB-EGF inhibitors derived from the R domain of diphtheria toxin for the treatment of diseases associated with activation of the HB-EGF / EGFR pathway
US14/386,470 US9758552B2 (en)	2012-03-20	2013-03-19	HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway
EP13720081.2A EP2828285B1 (en)	2012-03-20	2013-03-19	Hb-egf inhibitor derived from diphtheria toxin r domain for the treatment of diseases associated with the activation of hb-egf/egfr pathway.
PCT/IB2013/052173 WO2013140335A1 (en)	2012-03-20	2013-03-19	Hb-egf inhibitor derived from the r domain of diphtheria toxin for the treatment of diseases associated with the activation of the hb-egf/egfr pathway
DK13720081.2T DK2828285T3 (en)	2012-03-20	2013-03-19	HB-EGF INHIBITOR DERIVED FROM DIFTERY TOXIN R DOMAIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF HB-EGF / EGFR SIGNAL ROAD
ES13720081.2T ES2679168T3 (en)	2012-03-20	2013-03-19	HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF / EGFR pathway
TR2018/10352T TR201810352T4 (en)	2012-03-20	2013-03-19	Hb-egf inhibitor derived from the domain of diphtheria toxin for the treatment of diseases associated with activation of the hb-egf egfr pathway.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1252497A FR2988393B1 (en)	2012-03-20	2012-03-20	INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT

Publications (2)

Publication Number	Publication Date
FR2988393A1 FR2988393A1 (en)	2013-09-27
FR2988393B1 true FR2988393B1 (en)	2014-05-09

Family

ID=48237170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR1252497A Expired - Fee Related FR2988393B1 (en)	2012-03-20	2012-03-20	INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT

Country Status (8)

Country	Link
US (1)	US9758552B2 (en)
EP (1)	EP2828285B1 (en)
JP (1)	JP6279543B2 (en)
DK (1)	DK2828285T3 (en)
ES (1)	ES2679168T3 (en)
FR (1)	FR2988393B1 (en)
TR (1)	TR201810352T4 (en)
WO (1)	WO2013140335A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017510290A (en) *	2014-01-31	2017-04-13	フィナバイオソリューションズリミテッドライアビリティカンパニー	Expression and purification of CRM197 and related proteins
US12104161B2 (en)	2014-01-31	2024-10-01	Fina Biosolutions Llc	Production of soluble recombinant proteins without N-terminal methionine in E-coli
US11060123B2 (en)	2014-01-31	2021-07-13	Fina Biosolutions, Llc	Production of soluble recombinant protein without n-terminal methionine
JP6369862B2 (en) *	2014-08-06	2018-08-08	原　英彰	Intraocular angiogenesis inhibitor and use thereof
KR102078714B1 (en) *	2018-02-02	2020-02-19	(주)포바이오코리아	Recovery and purification method of bioactive crm197 proteins from inclusion bodies including crm197
WO2025012415A1 (en) *	2023-07-12	2025-01-16	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Combination of a hb-egf inhibitor and a corticosteroid agent for the treatment of kidney diseases associated with activation of the hb-egf/egfr pathway

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0643559B1 (en) *	1992-05-06	1999-04-14	The President And Fellows Of Harvard College	Diphtheria toxin receptor-binding region
US5917017A (en)	1994-06-08	1999-06-29	President And Fellows Of Harvard College	Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) *	1994-06-08	2002-09-24	President And Fellows Of Harvard College	Multi-mutant diphtheria toxin vaccines
AU6906100A (en) *	1999-08-16	2001-03-13	Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The	Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
JP4203742B2 (en) *	2002-10-15	2009-01-07	財団法人阪大微生物病研究会	Anticancer drug
US20060270600A1 (en)	2005-05-26	2006-11-30	Eisuke Mekada	Anti-cancer agents
AU2006260240B2 (en)	2005-06-21	2012-03-15	The Research Foundation For Microbial Diseases Of Osaka University	Therapeutic agent for cancer
AU2007257646B2 (en)	2006-06-06	2011-08-11	Kyowa Hakko Kirin Co., Ltd.	Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
EP2093237B1 (en)	2006-10-20	2015-12-30	Chugai Seiyaku Kabushiki Kaisha	Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
EP3040347A3 (en)	2006-10-20	2016-09-21	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
EP2077842A2 (en)	2006-10-31	2009-07-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of an egfr antagonist for the treatment of glomerolonephritis
EP2497783A3 (en)	2007-09-26	2013-04-17	U3 Pharma GmbH	Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
CN101978054B (en)	2007-12-05	2013-05-29	协和发酵麒麟株式会社	Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
GB0807018D0 (en)	2008-04-17	2008-05-21	Fusion Antibodies Ltd	Antibodies and treatment
FR2940451B1 (en)	2008-12-18	2014-09-12	Proteus	METHOD FOR EVALUATING IMMUNOGENICITY OF PROTEINS
EP2468771A4 (en)	2009-08-17	2013-06-05	Forerunner Pharma Res Co Ltd	PHARMACEUTICAL COMPOSITION CONTAINING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT

2012
- 2012-03-20 FR FR1252497A patent/FR2988393B1/en not_active Expired - Fee Related
2013
- 2013-03-19 TR TR2018/10352T patent/TR201810352T4/en unknown
- 2013-03-19 ES ES13720081.2T patent/ES2679168T3/en active Active
- 2013-03-19 DK DK13720081.2T patent/DK2828285T3/en active
- 2013-03-19 WO PCT/IB2013/052173 patent/WO2013140335A1/en active Application Filing
- 2013-03-19 JP JP2015501031A patent/JP6279543B2/en active Active
- 2013-03-19 US US14/386,470 patent/US9758552B2/en active Active
- 2013-03-19 EP EP13720081.2A patent/EP2828285B1/en active Active

Also Published As

Publication number	Publication date
FR2988393A1 (en)	2013-09-27
US9758552B2 (en)	2017-09-12
DK2828285T3 (en)	2018-07-30
EP2828285B1 (en)	2018-04-25
TR201810352T4 (en)	2018-08-27
WO2013140335A1 (en)	2013-09-26
EP2828285A1 (en)	2015-01-28
JP6279543B2 (en)	2018-02-14
US20150051146A1 (en)	2015-02-19
JP2015512382A (en)	2015-04-27
ES2679168T3 (en)	2018-08-22

Publication	Publication Date	Title
FR22C1002I2 (en)	2024-03-08	IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
FR22C1011I1 (en)	2022-05-06	FUMARATE PRODRUGS AND THEIR USE FOR THE TREATMENT OF VARIOUS DISEASES
EP3370703A4 (en)	2019-06-19	COMBINATION OF GEMCABEN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP2773342A4 (en)	2015-08-26	COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
EP2709672A4 (en)	2014-12-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINA DISEASES
ME03314B (en)	2019-10-20	RNA-BASED THERAPY FOR THE TREATMENT OF EYE DISEASES
MA51418A (en)	2020-11-04	GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES
EP2717903A4 (en)	2015-04-29	TREATMENT METHODS FOR RETINAL DISEASES
EP2861240A4 (en)	2016-03-16	NUCLEIC ACIDS FOR THE TREATMENT OF ALLERGIES
MA40957A (en)	2017-09-19	HEPARANE SULPHATE BIOSYNTHESIS INHIBITORS TO TREAT DISEASES
EP2623494A4 (en)	2014-04-02	AGENT FOR THE TREATMENT OF OCULAR DISEASES
EP2671586A4 (en)	2014-10-22	PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
EP2983791A4 (en)	2016-11-09	METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2661494A4 (en)	2015-03-25	PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIS AND OTHER DISEASES
MA56412A (en)	2022-05-04	MESSENGER RNA THERAPY FOR THE TREATMENT OF JOINT DISEASES
EP3316887A4 (en)	2019-01-16	GLS1 INHIBITORS FOR THE TREATMENT OF DISEASES
EP2691529A4 (en)	2014-12-10	METHODS AND COMPOSITIONS FOR TREATING CEREBRAL DISEASES
EP2515926A4 (en)	2013-10-09	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-RELATED OPHTHALMIC DISEASES
FR2988393B1 (en)	2014-05-09	INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT
EP2967062A4 (en)	2016-10-19	DEETHYLHYDROXYCHLOROQUINE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION
EP2922534A4 (en)	2016-05-11	METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP2925889A4 (en)	2016-06-15	DIAGNOSTIC MARKERS FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS BY TELOMERASE INHIBITORS
FR20C1044I2 (en)	2021-10-15	TRIAZINES FOR THE TREATMENT OF PROTOZOIC INFECTIONS
MA53568A (en)	2022-02-23	DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
EP2544686A4 (en)	2013-06-26	COMBINED METHODS FOR THE TREATMENT OF DISEASES

Legal Events

Date	Code	Title	Description
2015-03-31	PLFP	Fee payment	Year of fee payment: 4
2016-03-31	PLFP	Fee payment	Year of fee payment: 5
2017-03-27	PLFP	Fee payment	Year of fee payment: 6
2018-03-27	PLFP	Fee payment	Year of fee payment: 7
2019-02-27	PLFP	Fee payment	Year of fee payment: 8
2020-12-18	ST	Notification of lapse	Effective date: 20201109